Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $115.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price hoisted by investment analysts at HC Wainwright from $95.00 to $115.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 34.10% from the company’s current price.

A number of other research firms also recently commented on HALO. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 31st. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $83.60.

Halozyme Therapeutics Stock Up 2.6%

Shares of Halozyme Therapeutics stock opened at $85.76 on Friday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $86.00. The business’s fifty day moving average price is $75.74 and its two-hundred day moving average price is $71.25. The company has a market capitalization of $10.17 billion, a P/E ratio of 30.85, a PEG ratio of 0.35 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period last year, the company earned $1.54 earnings per share. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts forecast that Halozyme Therapeutics will post 7.54 EPS for the current year.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares in the company, valued at approximately $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 72,477 shares of company stock worth $5,102,643 in the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics in the 2nd quarter worth about $28,000. OneDigital Investment Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $254,000. Chase Investment Counsel Corp acquired a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $2,035,000. Horizon Investment Services LLC purchased a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $2,254,000. Finally, Global Retirement Partners LLC purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at $476,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record quarterly results exceeded expectations. Second-quarter revenue rose 48% year over year to $481 million, beating estimates of approximately $402 million. Adjusted earnings reached $2.28 per diluted share, above consensus estimates ranging from $1.79 to $1.82 and up from $1.54 a year earlier. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Royalty growth remained a key catalyst. Royalty revenue increased 50% year over year to $308 million, highlighting continued commercial adoption of Halozyme’s drug-delivery technologies and the scalability of its royalty-based business. Halozyme Q2 Key Metrics
• Positive Sentiment: Management raised 2026 guidance. Halozyme now expects total revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP EPS of $8.65 to $9.00. The EPS outlook is well above the roughly $8.02 analyst consensus. Halozyme Q2 2026 Results Presentation
• Positive Sentiment: Business development exceeded targets. The company signed five new ENHANZE and Hypercon collaboration agreements during 2026, already surpassing its goal of three agreements for the full year. This could strengthen Halozyme’s longer-term pipeline and royalty growth prospects. Halozyme Q2 2026 Earnings Call Transcript

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.